Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US75062E1064
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00J3YYS92
RFL
Rafael Holdings Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Real Estate Services · THEMEFOLIO: $HLTH
NAME
Rafael Holdings Inc
ISIN
US75062E1064
TICKER
RFL
MIC
XNYS
REUTERS
RFL.N
BLOOMBERG
RFL US
Di., 03.11.2026       Rafael
US75062E1064

NEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Monday, November 9, 2026 at 3:55 p.m. ET, and host one-on-one meetings with institutional investors....
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 29.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investi...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 29.10.2026       Rafael
US75062E1064

NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026....
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 29.10.2026       Rafael
US75062E1064

NDA supported by the Phase 3 TransportNPC™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 22.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or  the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The invest...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 15.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Rafael and certain of its officers and/or...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 08.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Rafael and certain of its officers and/or di...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 30.09.2026       Rafael
US75062E1064

Please post to IR news on company website and send to excel distribution list on file. Thank you. Best, Barbara...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Rafael
US75062E1064

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026....
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 10.06.2026       Rafael
US75062E1064

Topline results are expected to be announced in second half of calendar 2026...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 22.04.2026       Rafael
US75062E1064

License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Rafael
US75062E1064

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026....
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Rafael
US75062E1064

NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025....
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 29.10.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Rafael
US75062E1064

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15th International Congress...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 11.06.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this month Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatme...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 26.03.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the tr...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 13.03.2025       Rafael
US75062E1064

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 11.12.2024       Rafael
US75062E1064

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 07.11.2024       Rafael
US75062E1064

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 22.08.2024       Rafael
US75062E1064

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Rafael Holdings, Inc. (NYSE: RFL) and Cyclo Therapeutics, Inc. is fair to Rafael shareholders. Halper Sadeh encourages Rafael shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 22.08.2024       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Fr., 14.06.2024       Rafael
US75062E1064

Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mi., 23.03.2022       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - March 23, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Rafael and certain o...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mo., 14.03.2022       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - March 14, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Rafael and certain o...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mo., 18.10.2021       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE: RFL) stock prior to August 16, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an invest...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Do., 26.08.2021       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - August 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE: RFL) stock prior to August 16, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investi...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink
Mo., 28.06.2021       Rafael
US75062E1064

Philadelphia, Pennsylvania--(Newsfile Corp. - June 28, 2021) - Kaskela Law LLC announces that it is investigating Rafael Holdings, Inc. ("Rafael Holdings") (NYSE: RFL) on behalf of the company's stockholders.On June 21, 2021, Rafael Holdings announced that it had entered into an agreement to acquire Rafael Pharmaceuticals, Inc. ("Pharmaceuticals")...
Zur Nachricht
Rafael
Charts & Research Termsheets Terminal
Permalink